China's Biotech Moment Ignites a 60% Stock Rally That Beats AI
China's biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains.
The Hang Seng Biotech Index has surged more than 60% since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector's appeal.
'China biotech is no longer just an emerging story — unlike 10 years ago — it is now a disruptive force reshaping global drug innovation,' said Yiqi Liu, senior investment analyst at Exome Asset Management LLC in New York. 'The science is real, the economics are compelling, and the pipeline is starting to deliver.'
The surge in China-listed biotech firms is further evidence that the mainland is becoming a center for global innovation. The rally in the sector this year outpaces the 17% gain in China's tech stocks that was driven by the release of DeepSeek's breakthrough artificial-intelligence app in January.
A major reason for the share gains were two mega-sized licensing deals. Pfizer Inc. said on May 19 it had agreed to pay a record $1.25 billion to license an experimental cancer drug from China's 3SBio Inc., and also invest $100 million in the firm's shares. Two weeks later, Bristol-Myers Squibb Co. said it would pay Germany's BioNTech SE as much as $11.5 billion to license a cancer drug that BioNTech had itself licensed from China's Biotheus Inc. in 2023.
Some of the gains in biotech shares this year have been stratospheric. 3SBio has surged 283%, topping a Bloomberg gauge of global biotech stocks. RemeGen Co., which develops antibody drugs, has climbed more than 270% after saying it was approached by multinational pharmaceutical firms for potential licensing deals.
China's growing influence through pharmaceutical mergers and acquisitions and deal-making is also causing investors to take note. In the first quarter alone, the value of such deals involving local players doubled from the year before to $36.9 billion. That amount made up more than half the global total of $67.5 billion.
Chinese biotech companies are having 'their own DeepSeek moment,' said Dong Chen, chief Asia strategist at Pictet Wealth Management in Hong Kong. There is more upside from here, he said.
Investor interest in biotech — which involves the use living organisms to make medicines and other products — can be seen in the big runup at recent initial public offerings.
Shares of Duality Biotherapeutics Inc., which develops cancer treatments, more than doubled on their first day of trading in Hong Kong on April 15. Jiangsu Hengrui Pharmaceuticals Co., the nation's largest drugmaker by market value, saw its stock jump 25% on debut May 23, even after being issued at the top end of the marketed range. Duality has now risen 189% since its IPO, while Jiangsu has gained 31%.
Still, some say the rally may be getting stretched.
'Bears, mostly healthcare specialists, plan to take profit at this point, and some investors prefer the healthcare laggers with capability of constant dividend payout and stable revenue growth,' Bank of America Corp. analysts including Ethan Cui in Hong Kong wrote in a research note this month.
Some investors also said they viewed the rush of recent licensing deals as a one-off, and they were refusing to grant valuation multiples to the companies, the analysts wrote.
While the recent ratcheting up of trade tensions between the US and China has been a negative for many mainland firms, it's also resulted in talent flowing back to China and creating more research-and-development capability, according to Nicholas Chui, a Chinese equity fund manager at Franklin Templeton in Hong Kong.
Jefferies is also bullish, saying the increase in US tariffs is unlikely to prove an obstacle to Chinese biotech firms.
Many of the Chinese biotech companies already have US partners and are therefore considered as service providers rather than product exporters, said Cui Cui, head of Asia healthcare research at the company in New York.
With assistance from Dong Lyu.
This article was generated from an automated news agency feed without modifications to text.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Add Basil Seeds Into Your Diet To Keep Your Gut, Skin And Body In Check
Last Updated: Basil seeds have long been used in cooking and Ayurveda. These tiny black seeds are a game-changer for your body during summers. Sabja seeds, also known as basil seeds, have long been used in cooking and Ayurveda. Their benefits, however, aren't just limited to Indian traditions; basil plants also hold a significant place in Chinese medicine. They may look like sesame seeds, but these tiny black seeds are a powerhouse of health benefits. Especially in this heat-scorched summer, basil seeds can truly be a game-changer for your body. From naturally cooling your system to supporting digestion, sabja seeds have a lot to offer. What Do Basil Seeds Contain? Minerals: Basil seeds are rich in essential minerals like magnesium, iron, and calcium. Including them in your daily diet can help boost nutrient levels, especially for those following a vegan lifestyle. Fibre: They are high in fibre. Just 1 tablespoon of basil seeds offers about 7 grams. This promotes gut health, helps regulate blood sugar levels and maintains healthy cholesterol. Plant Compounds: These tiny seeds are loaded with flavonoids and polyphenols – powerful antioxidants that protect against cell damage. According to Healthline, these compounds also carry anti-inflammatory and potential anti-cancer properties. Omega-3 Fat: Basil seeds are a plant-based source of Omega-3 fatty acids. Just one tablespoon every day can fulfil your daily requirement of ALA (alpha-linolenic acid). Health Benefits Of Consuming Basil Seeds Natural cooler: Basil seeds act as a natural body coolant in harsh summers. As per the International Journal of Scientific Research and Reviews, these seeds can absorb and retain water, helping cool down the body from within. Add them to your summer drinks and feel the difference. Natural Detoxifier: Sabja seeds help flush out toxins from the body. A study published in the Journal of Food Science and Technology highlights that the fibre in basil seeds supports gut cleansing and detoxification. Weight Management: Much like chia seeds, sabja seeds support weight management. High fibre keeps you full longer, making it a smart addition to your weight-loss plan. Promotes Healthy Skin: Basil seeds are rich in antioxidants, which help protect skin from sun damage and reduce inflammation. How to Eat Basil Seeds? They have long been used in drinks across India and Southeast Asia. It's very easy to include them in your everyday meals. Soak a teaspoon of sabja seeds in water for 15 minutes until they swell up, and then mix them into lemonades or smoothies. Add them as toppings on your dessert for a sweet yet healthy bite. Use them as a dressing on salads. Mix in yoghurt. Add to hot cereals like oatmeal. Sprinkle on whole-grain pancakes or pasta dishes. First Published: June 15, 2025, 16:16 IST
NDTV
2 hours ago
- NDTV
US-China Trade Talks Leave Military-Use Rare Earth Issue Unsettled: Sources
Beijing: The renewed US-China trade truce struck in London left a key area of export restrictions tied to national security untouched, an unresolved conflict that threatens a more comprehensive deal, two people briefed on detailed outcomes of the talks told Reuters. Beijing has not committed to grant export clearance for some specialized rare-earth magnets that US military suppliers need for fighter jets and missile systems, the people said. The United States maintains export curbs on China's purchases of advanced artificial intelligence chips out of concern that they also have military applications. At talks in London last week, China's negotiators appeared to link progress in lifting export controls on military-use rare earth magnets with the longstanding US curbs on exports of the most advanced AI chips to China. That marked a new twist in trade talks that began with opioid trafficking, tariff rates and China's trade surplus, but have since shifted to focus on export controls. In addition, US officials also signalled they are looking to extend existing tariffs on China for a further 90 days beyond the August 10 deadline agreed in Geneva last month, both sources said, suggesting a more permanent trade deal between the world's two largest economies is unlikely before then. The two people who spoke to Reuters about the London talks requested not to be named because both sides have tightly controlled disclosure. The White House, State Department and Department of Commerce did not immediately respond to requests for comment. China's Foreign and Commerce ministries did not respond to faxed requests for comment. President Donald Trump said on Wednesday the handshake deal reached in London between American and Chinese negotiators was a "great deal," adding, "we have everything we need, and we're going to do very well with it. And hopefully they are too." And US Treasury Secretary Scott Bessent said there would be no "quid pro quo" on easing curbs on exports of AI chips to China in exchange for access to rare earths. China Chokehold But China's chokehold on the rare earth magnets needed for weapons systems remains a potential flashpoint. China dominates global production of rare earths and holds a virtual monopoly on refining and processing. A deal reached in Geneva last month to reduce bilateral tariffs from crushing triple-digit levels had faltered over Beijing's restrictions on critical minerals exports that took shape in April. That prompted the Trump administration to respond with export controls preventing shipments of semiconductor design software, jet engines for Chinese-made planes and other goods to China. At the London talks, China promised to fast-track approval of rare-earth export applications from non-military US manufacturers out of the tens of thousands currently pending, one of the sources said. Those licenses will have a six-month term. Beijing also offered to set up a "green channel" for expediting license approvals from trusted US companies. Initial signals were positive, with Chinese rare-earths magnet producer JL MAG Rare-Earth, saying on Wednesday it had obtained export licences that included the United States, while China's Commerce Ministry confirmed it had approved some "compliant applications" for export licences. But China has not budged on specialized rare earths, including samarium, which are needed for military applications and are outside the fast-track agreed in London, the two people said. Automakers and other manufacturers largely need other rare earth magnets, including dysprosium and terbium. Big Issues Remain The rushed trade meeting in London followed a call last week between Trump and Chinese leader Xi Jinping. Trump said US tariffs would be set at 55% for China, while China had agreed to 10% from the United States. Trump initially imposed tariffs on China as punishment for its massive trade surplus to the United States and over what he says is Beijing's failure to stem the flow of the powerful opioid fentanyl into the US Chinese analysts are pessimistic about the likelihood of further breakthroughs before the August 10 deadline agreed in Geneva. "Temporary mutual accommodation of some concerns is possible but the fundamental issue of the trade imbalance cannot be resolved within this timeframe, and possibly during Trump's remaining term," said Liu Weidong, a US-China expert at the Institute of American Studies, Chinese Academy of Social Sciences. An extension of the August deadline could allow the Trump administration more time to establish an alternative legal claim for setting higher tariffs on China under the Section 301 authority of the USTR in case Trump loses the ongoing legal challenge to the tariffs in US court, one of the people with knowledge of the London talks said. The unresolved issues underscore the difficulty the Trump administration faces in pushing its trade agenda with China because of Beijing's control of rare earths and its willingness to use that as leverage with Washington, said Ryan Hass, director of the John L. Thornton China Center at the Brookings Institution. "It has taken the Trump team a few punches in the nose to recognise that they will no longer be able to secure another trade agreement with China that disproportionately addresses Trump's priorities," Hass said.
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Pak claim of downing 3 Rafales during Op Sindoor incorrect: Dassault CEO
Dassault Aviation CEO Eric Trappier says Rafale is better than the American F-35 stealth jet and far superior to all Chinese aircraft in the market when it comes to being an omnirole aircraft Delhi Listen to This Article Pakistan's claims of downing three Indian Air Force (IAF) Rafale combat aircraft in an aerial engagement during the May 7 strike on terror targets inside Pakistan under Operation Sindoor are incorrect, Éric Trappier, chief executive officer (CEO) of France's Dassault Aviation, the original equipment manufacturer of Rafale, has said. Acknowledging that he was not exactly aware about the alleged combat losses during Operation Sindoor — given that New Delhi has not communicated anything on the matter — Trappier said in a French-language interview: 'What we do know is that the claims made by the Pakistanis (three Rafales destroyed) are incorrect.'
